Advertisements


Spark Therapeutics shares jump 7.5% after FDA committee backs blindness treatment

Shares of Spark Therapeutics Inc. surged 7.5% premarket Friday, after a U.S. Food and Drugs Administration advisory committee recommended approval of the company's gene therapy treatment for a rare eye disease that causes blindness. .....»»

Category: topSource: marketwatchOct 13th, 2017

Spark Therapeutics shares halted as FDA committee reviews gene therapy treatment for eye disease

Spark Therapeutics Inc. shares were halted Thursday as a U.S. Food and Drugs Administration advisory committee meets to review the company's gene therapy treatment for patients with vision loss caused.....»»

Category: topSource: marketwatchOct 12th, 2017

Stemline Therapeutics shares jump 4% premarket after positive trial of leukemia treatment

Shares of biotech Stemline Therapeutics Inc. jumped 4% premarket Wednesday, after the company said a trial of a treatment for acute myeloid leukemia met its main goal. Stemline said d.....»»

Category: topSource: marketwatchDec 13th, 2017

Spark Therapeutics shares slide more than 40% after hemophilia data disappoint

Shares of gene therapy biotech Spark Therapeutics Inc. tumbled more than 40% in early trade Monday, after it reported data from trials of a hemophilia treatment that analysts said look less competitive than a rival product from BioMarin Pharma.....»»

Category: topSource: marketwatchDec 11th, 2017

All The Sell-Side Responses To Spark Therapeutics" Strong AdCom Meeting On Luxturna

On Thursday afternoon, and FDA advisory panel recommended approval of Spark Therapeutics Inc (NASDAQ: ONCE)’s Luxturna treatment for inherited blindness. Latest Ratings for ONCE.....»»

Category: blogSource: benzingaOct 13th, 2017

Spark Therapeutics shares halted as FDA advisory committee reviews gene therapy

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchOct 12th, 2017

Spark Therapeutics applies to market investigational therapy in Europe

The gene therapy company that spun out of Children's Hospital of Philadelphia is moving forward with a regulatory review of its treatment of an inherited disease that leads to blindness in Europe – laying the groundwork for the investigational therapy .....»»

Category: topSource: bizjournalsJul 31st, 2017

Why Spark"s CEO says 2017 may be a "historic year" for his gene therapy company

Philadelphia gene therapy company Spark Therapeutics said it is in the final stages of completing its rolling biologics license application for its lead product: a one-time treatment for an inherited retinal disease that causes blindness in children.....»»

Category: topSource: bizjournalsFeb 22nd, 2017

Pluristem shares jump 5.4% premarket as FDA approves trial of treatment for critical limb ischemia

Pluristem Therapeutics Inc. shares surged 5.4% in premarket trade Tuesday, after the company said the U.S. Food and Drug Administration has granted approval for a late-stage trial of PLX-PAD cells in the treatme.....»»

Category: topSource: marketwatchJan 10th, 2017

Stemline Therapeutics shares jump 4% premarket

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchDec 13th, 2017

UBS Loses Conviction In Spark Therapeutics, Downgrades

Spark Therapeutics Inc (NASDAQ: ONCE) released phase 1/2 SPK-8011 data in hemophilia A treatment over the weekend that fell short of what investors had hoped for. Late.....»»

Category: blogSource: benzingaDec 12th, 2017

Apple and Chesapeake Energy rise; Spark Therapeutics sinks

Stocks that moved substantially or traded heavily Monday: Bluebird Bio Inc., up $30.65 to $201.80 Bluebird and Celgene reported positive results from an early clinical trial of a multiple myeloma treatment......»»

Category: topSource: foxnewsDec 11th, 2017

Why Spark Therapeutics stock price dropped by 40% this morning

Spark Therapeutics’ stock price plunged more than 40 percent Monday morning after the Philadelphia-based gene therapy company provided an update of its experimental hemophilia A treatment. Preliminary clinical data showed the gene therapy treat.....»»

Category: topSource: bizjournalsDec 11th, 2017

UniQure shares jump 3.8% premarket on positive trial of hemophelia treatment

UniQure N.V. shares surged almost 4% in premarket trade Monday, after the company reported positive results in an early-stage trial of a treatment for .....»»

Category: topSource: marketwatchDec 11th, 2017

Lighting a Spark for Gene Therapy

A treatment for hemophilia B being developed by Spark Therapeutics and Pfizer gets highlighted in The New England Journal of Medicine......»»

Category: topSource: barronsDec 8th, 2017

UPDATE: Sage Therapeutics shares soar more than 74% on positive trial of depression treatment

Sage Therapeutics Inc. shares soared more than 74% in premarket trade Thursday, after the c.....»»

Category: topSource: marketwatchDec 7th, 2017

Viking Therapeutics stock surges 18% premarket on positive trial of hip fracture treatment

Shares of Viking Therapeutics Inc. surged 18% in premarket trade Tuesday.....»»

Category: topSource: marketwatchNov 28th, 2017

This Gene Therapy Can Restore Vision, but Will It Break the Bank?

If Spark Therapeutics' game-changing new treatment Luxturna gets FDA approval in January, it may launch with an eye-popping price tag......»»

Category: topSource: foxnewsNov 8th, 2017

Sarepta Takes Another Big Step Forward With DMD Treatment

Sarepta Therapeutics saw its shares hit a new multiyear high on Friday after the firm announced that it received a key approval from the FDA......»»

Category: blogSource: 247wallstNov 3rd, 2017

Shares jump after China backs down from protesting South Korean companies over US missile defense deployment

Seoul and Beijing have agreed to .....»»

Category: topSource: businessinsiderOct 31st, 2017

Wells Fargo Shares Dip As Bank Fires 4 FX Traders Following Investigations

Wells Fargo CEO Tim Sloan received the patented Elizabeth Warren treatment during testimony before the Senate Banking Committee last month when the Massachusetts Senator accused h.....»»

Category: blogSource: zerohedgeOct 20th, 2017